Systemic Amyloidoses

Overview

Journal Annu Rev Biochem

Publisher Annual Reviews

Specialty Biochemistry

Date 2013 Mar 5

PMID 23451869

Citations 99

Authors

Luis M Blancas-Mejia

Marina Ramirez-Alvarado

Affiliations

Soon will be listed here.

Abstract

The amyloidoses are a group of protein misfolding diseases in which the precursor protein undergoes a conformational change that triggers the formation of amyloid fibrils in different tissues and organs, causing cell death and organ failure. Amyloidoses can be either localized or systemic. In localized amyloidosis, amyloid deposits form at the site of precursor protein synthesis, whereas in systemic amyloidosis, amyloid deposition occurs distant from the site of precursor protein secretion. We review the type of proteins and cells involved and what is known about the complex pathophysiology of these diseases. We focus on light chain amyloidosis to illustrate how biochemical and biophysical studies have led to a deeper understanding of the pathogenesis of this devastating disease. We also review current cellular, tissue, and animal models and discuss the challenges and opportunities for future studies of the systemic amyloidoses.

Citing Articles

Hereditary transthyretin amyloidosis incidentally diagnosed by video-associated lung surgery for lung cancer: A case report.

Itogawa K, Sato S, Yamakawa H, Akasaka K, Amano M, Adachi A Respir Med Case Rep. 2025; 53:102170.

PMID: 39980614 PMC: 11841070. DOI: 10.1016/j.rmcr.2025.102170.

Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease-Protein-Drug Network.

Rizou A, Nasi G, Apostolakou A, Dimopoulos M, Kastritis E, Iconomidou V Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770578 PMC: 11677318. DOI: 10.3390/ph17121736.

Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis.

Morgan G, Yung Z, Spencer B, Sanchorawala V, Prokaeva T Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598451 PMC: 11597191. DOI: 10.3390/ph17111542.

Interconnection of the Gut-Skin Axis in NC/Nga Mouse with Atopic Dermatitis: Effects of the Three Types of CBT-BF3 (Probiotics, Postbiotics, and Cytosine-Phosphate-Guanine Oligodeoxynucleotide) on T Cell Differentiation and Gut Microbiota.

Kim G, Jeong H, Kim I, Lee S, Kim S, Moon Y Food Sci Anim Resour. 2024; 44(6):1417-1439.

PMID: 39554831 PMC: 11564143. DOI: 10.5851/kosfa.2024.e100.

Cryo-EM structure of a lysozyme-derived amyloid fibril from hereditary amyloidosis.

Karimi-Farsijani S, Sharma K, Ugrina M, Kuhn L, Pfeiffer P, Haupt C Nat Commun. 2024; 15(1):9648.

PMID: 39511224 PMC: 11543692. DOI: 10.1038/s41467-024-54091-7.

References

Bellotti V, Mangione P, Merlini G . Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability. J Struct Biol. 2000; 130(2-3):280-9. DOI: 10.1006/jsbi.2000.4248. View

Morgan C, Gelfand M, Atreya C, Miranker A . Kidney dialysis-associated amyloidosis: a molecular role for copper in fiber formation. J Mol Biol. 2001; 309(2):339-45. DOI: 10.1006/jmbi.2001.4661. View

Wetzel R . Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem. 1997; 50:183-242. DOI: 10.1016/s0065-3233(08)60322-8. View

Buxbaum J . Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992; 6(2):323-46. View

Khurana R, Gillespie J, Talapatra A, Minert L, Millett I, Fink A . Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry. 2001; 40(12):3525-35. DOI: 10.1021/bi001782b. View

Bork P, Holm L, Sander C . The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol. 1994; 242(4):309-20. DOI: 10.1006/jmbi.1994.1582. View

Powers E, Morimoto R, Dillin A, Kelly J, Balch W . Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. 2009; 78:959-91. DOI: 10.1146/annurev.biochem.052308.114844. View

Sikkink L, Ramirez-Alvarado M . Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis. 2011; 1:e98. PMC: 3032327. DOI: 10.1038/cddis.2010.75. View

Sitia R, Neuberger M, Alberini C, Bet P, Fra A, Valetti C . Developmental regulation of IgM secretion: the role of the carboxy-terminal cysteine. Cell. 1990; 60(5):781-90. DOI: 10.1016/0092-8674(90)90092-s. View

10.

Lai Z, McCulloch J, Lashuel H, Kelly J . Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry. 1997; 36(33):10230-9. DOI: 10.1021/bi963195p. View

11.

TERRY C, Damas A, Oliveira P, Saraiva M, Alves I, Costa P . Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J. 1993; 12(2):735-41. PMC: 413260. DOI: 10.1002/j.1460-2075.1993.tb05707.x. View

12.

Kim Y, Cape S, Chi E, Raffen R, Stevens F, Manning M . Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J Biol Chem. 2000; 276(2):1626-33. DOI: 10.1074/jbc.M007766200. View

13.

Connors L, Lim A, Prokaeva T, Roskens V, Costello C . Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003; 10(3):160-84. DOI: 10.3109/13506120308998998. View

14.

Johnson S, Connelly S, Fearns C, Powers E, Kelly J . The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012; 421(2-3):185-203. PMC: 3350832. DOI: 10.1016/j.jmb.2011.12.060. View

15.

Feige M, Hendershot L, Buchner J . How antibodies fold. Trends Biochem Sci. 2009; 35(4):189-98. PMC: 4716677. DOI: 10.1016/j.tibs.2009.11.005. View

16.

Kim Y, Wall J, Meyer J, Murphy C, Randolph T, Manning M . Thermodynamic modulation of light chain amyloid fibril formation. J Biol Chem. 2000; 275(3):1570-4. DOI: 10.1074/jbc.275.3.1570. View

17.

Obici L, Perfetti V, Palladini G, Moratti R, Merlini G . Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005; 1753(1):11-22. DOI: 10.1016/j.bbapap.2005.08.014. View

18.

Davis P, Raffen R, Dul L, Vogen M, Williamson K, Stevens J . Inhibition of amyloid fiber assembly by both BiP and its target peptide. Immunity. 2000; 13(4):433-42. DOI: 10.1016/s1074-7613(00)00043-1. View

19.

Peterson F, Baden E, Owen B, Volkman B, Ramirez-Alvarado M . A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. Structure. 2010; 18(5):563-70. PMC: 2872106. DOI: 10.1016/j.str.2010.02.012. View

20.

Abraham R, Geyer S, Price-Troska T, Allmer C, Kyle R, Gertz M . Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003; 101(10):3801-8. DOI: 10.1182/blood-2002-09-2707. View